| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2803124001018 | 312400101 | PEMETREXED LILLY PD.C.SO.IN 100MG/VIAL BTx1 VIAL (γυάλινο) | 108.00 | 113.29 | 139.31 |
| 05/2018 | 2803124002015 | 312400201 | PEMETREXED LILLY PD.C.SO.IN 500MG/VIAL BTx1 VIAL (γυάλινο) | 558.06 | 566.44 | 648.47 |
| 05/2018 | 2803133201010 | 313320101 | PEMETREXED HOSPIRA PD.C.SO.IN 100MG/VIAL BTx1 VIAL | 108.00 | 113.29 | 139.31 |
| 05/2018 | 2803133202017 | 313320201 | PEMETREXED HOSPIRA PD.C.SO.IN 500MG/VIAL BTx1 VIAL | 558.06 | 566.44 | 648.47 |
| 05/2018 | 2803133203014 | 313320301 | PEMETREXED HOSPIRA PD.C.SO.IN 1000MG/VIAL BTx1 VIAL | 923.12 | 936.99 | 1047.84 |
| 05/2018 | 2803125502019 | 312550201 | PEMETREXED SANDOZ PD.C.SO.IN 500MG/VIAL BTx1 VIAL | 558.06 | 566.44 | 648.47 |
Used in combination with cisplatin for the treatment of malignant pleural mesothelioma in adults whose disease is unresectable or who otherwise are not candidates for potentially curative surgery. Also used as a monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy
Pemetrexed is an antifolate containing the pyrrolopyrimidine-based nucleus that exerts its antineoplastic activity by disrupting folate-dependent metabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), all folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is transported into cells by both the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT. Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, to a lesser extent, in normal tissues. Polyglutamated metabolites have an increased intracellular half-life resulting in prolonged drug action in malignant cells.
3.5 hours
Pemetrexed is not metabolized to an appreciable extent and is primarily eliminated in the urine, with 70% to 90% of the dose recovered unchanged within the first 24 hours following administration.
* 16.1 L
* 91.8 mL/min [Cancer patients with normal renal function receiving 0.2 to 838 mg/m2 infusion over a 10-minute period]